drugset
drugset / Trial / NCT03098953

Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Installations

NCT03098953 ↗

Phase 1 Completed 15 enrolled Bausch & Lomb Incorporated
NaSingle-groupOpen-labelTreatment

Summary

Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Instillations of Loteprednol Etabonate Ophthalmic Gel

Timeline

Start
2017-04-10
Primary completion
2017-05-12
Completion
2017-05-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Loteprednol Etabonate Other / unclassified 0.38 % Other

Indications

No indication recorded.